Jump to Main Content

Research


CAR-T Toxicities Consortium

The Chimeric Antigen Receptor T-Cell Therapies Toxicities Consortium unites investigators in scientific and medical associations, government agencies, and registries, to address emerging CAR-T-related toxicities as T-cell therapies continue to be used, as a treatment approach for hematologic malignancies. 

Goals and Objectives

The consortium, consisting of representatives from scientific and medical associations, U.S. Food and Drug Administration (FDA) and the Center for International Blood and Marrow Transplant Research (CIBMTR) working together, is meant to address urgent needs related to emerging CAR-T adverse events and identify opportunities to address the following areas:

  1. Increasing investigators’ understanding of the molecular mechanisms surrounding these toxicities and the role conditioning regimens could play in their onset.  
  2. Exploring ways to effectively report and catalog these toxicities to inform future research.  
  3. Developing educational resources for clinicians to inform toxicity management approaches.  
  4. Informing regulatory agencies on the challenges and recent developments in the field surrounding this topic. 

Current Focus

The consortium is expected to convene on a bi-monthly basis (i.e., every other month) with its first order of business being to conduct a landscape analysis of the field and that based on its assessment, it will then ascertain and develop resources to address important gaps. 

Consortium Members

The consortium consists of individuals who have expertise in CAR-T cells and the ability to carry forward recommendations from this consortium to their respective organizations.


American Society of Hematology


Nirali N. Shah, MD, MHSc, (Chair)

Robert S Negrin, MD, PhD, (Vice Chair)

Alice Kuaban, MS, (Staff Liason)

ASH Research Collaborative


Saad Usmani, MD, MBA, FACP, FASCO, (Chair)

William Wood, MD, MPH, (Vice Chair)

Food and Drug Administration


Nicole Verdun, MD, (Chair)

American Association for Cancer Research


Helen E. Heslop, MD, DSc (Hon), (Chair)

Nikhil C. Munshi, MD, (Vice Chair)

Maximilian F. Konig, MD, DSc (Hon), (Chair)

C. Thomas Appleton, MD, PhD, FRCPC, (Vice Chair)

American Society for Transplantation and Cellular Therapies


Frederick Locke, MD, (Chair)

Marcela Maus, MD, PhD, (Vice Chair)

Center for International Blood and Marrow Transplant Research


Marcelo Pasquini, MD, MS, (Chair)

American Society of Gene and Cell Therapies


Isabelle Riviere, PhD, (Chair)

Marco Davila, MD, PhD, (Vice Chair)

International Society for Cell and Gene Therapy


Bruce Levine, PhD, (Chair)

Jaap Jan Boelens, MD, PhD, (Vice Chair)

Society for Immunotherapy of
Cancer


Kristen Hege, MD, (Chair)

Sarah Warren, PhD, (Vice Chair)

Questions?

For more information on the Cart-T Toxicities Consortium, please contact ASH’s Director of Scientific Affairs, Alice Kuaban, MS at [email protected].